Login
$INO
$1.39 -$0.01 (0.71%) After hours

$INO 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights

09 Nov 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

Introductory. Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of (i) 58,747,235 shares of its common stock...

05 Nov 2026 8-K: Results of Operations and Financial Condition

Inovio Pharmaceuticals, Inc. (the “Company”) is providing the following financial information. As of September 30, 2026, the Company estimates that its cash, cash equivalents and short-term investments were approximately $48.4 million.

02 Nov 2026 8-K: Regulation FD Disclosure; Other Events

FDA Accelerated Approval of VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) Investor Call November 2, 2026 Exhibit 99.2

06 Oct 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

This Amendment (the “Amendment”) to the Amended and Restated Bylaws (the “Bylaws”) of Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), is made effective as of the date first above written in accordance with Artic...

12 Aug 2026 8-K: Results of Operations and Financial Condition

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

31 Jul 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Warrants to Purchase Up to 42,105,264 Shares of Common Stock (or Pre-Funded Warrants in lieu thereof)

29 Jul 2026 8-K: Results of Operations and Financial Condition

Inovio Pharmaceuticals, Inc. (the “Company”) is providing the following financial information. As of June 30, 2026, the Company estimates that its cash and cash equivalents were approximately $36.7 million.

20 May 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

The Amended and Restated Bylaws (the “Bylaws”) of INOVIO Pharmaceuticals, Inc., a Delaware corporation (the “Company”), are hereby amended as follows:

13 May 2026 8-K: Results of Operations and Financial Condition

INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights

06 Apr 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Series A Warrants to Purchase Up to 12,500,000 Shares of Common Stock (or Pre-Funded Warrants in lieu thereof)

02 Apr 2026 8-K: Other Events

On April 1, 2026 Inovio Pharmaceuticals, Inc. (the “Company”) notified Oppenheimer & Co. Inc. (the “Sales Agent”) that it was suspending and terminating the prospectus, dated August 13, 2024 (the “ATM Prospectus”), related to the sales a...

12 Mar 2026 8-K: Results of Operations and Financial Condition

PLYMOUTH MEETING, PA – March 12, 2026 – INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, to...

27 Jan 2026 8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders

THIS AMENDMENT TO THE WARRANT TO PURCHASE COMMON STOCK, dated January 27, 2026 (“Amendment”), amends that certain Series A Warrant, dated as of July 7, 2025 (the “Series A Warrant”), issued by Inovio Pharmaceuticals, Inc., a Delaware cor...

29 Dec 2025 8-K: Regulation FD Disclosure; Other Events

PLYMOUTH MEETING, PA., December 29, 2025 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infecti...

12 Nov 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement with Piper Sandler & Co. and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also ...

10 Nov 2025 8-K: Results of Operations and Financial Condition

PLYMOUTH MEETING, PA – November 10, 2025 – INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases,...

12 Aug 2025 8-K: Results of Operations and Financial Condition

PLYMOUTH MEETING, PA – August 12, 2025 – INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, t...

07 Jul 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Series A Warrants to Purchase Up to 14,285,715 Shares of Common Stock

22 May 2025 8-K: Submission of Matters to a Vote of Security Holders

On May 20, 2025, Inovio Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), at which the stockholders considered four proposals, each of which is described in more detail in the Comp...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support